Antithrombin and atherosclerosis in the Rotterdam study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 7, 1996, Pages 864-867

  Van der Bom, J G ^a   Bots, M L ^a   Van Vliet, H H D M ^a   Pols, H A P ^a   Hofman, A ^a   Grobbee, D E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cardiovascular disease; coagulation; hemostasis; risk

Indexed keywords

ANTITHROMBIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR DISEASE; CORONARY RISK; FEMALE; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; THROMBOSIS;

EID: 0030018701     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.7.864     Document Type: Article

References (36)

1. Meade TW, Broznovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellow S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
2. Wilhelmsen L, Svärdsudd K, Korsan-Bengsten K, Larsson B, Welin L, Libblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
3. Michiels JJ, van Vliet HHDM. Hereditary antithrombin III deficiency and venous thrombosis. Neth J Med. 1984;27:226-232.
4. Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M. Antithrombin III mutation database: first update, Thromb Haemost. 1993;70:361-369.
5. Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev. 1994;8:37-55.
6. Johnson EJ, Prentice CR, Paoapia LA. Premature arterial disease associated with familial antithrombin III deficiency. Thromb Haemost. 1990;63:13-15.
7. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke: a selective review. Stroke. 1990;21:1111-1121.
8. Banerjee R, Sahni A, Kumar V, Arya M. Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thromb Diath Haemorrhag. 1974;31:339-345.
9. ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study: baseline associations of hemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
10. Yue R, Gertler M, Starr T, Koutrouby R. Alterations of plasma antithrombin III levels in ischemic heart disease. Thromb Haemost. 1976;35:598-606.
11. Wu KK, Folsom AR, Heiss G, Davies CE, Conlan MG, Barnes R, for the ARIC Investigators. Association of coagulation factors and inhibitors with carotid artery atherosclerosis: early results of the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1992;2:471-480.
12. Meade TW. The epidemiology of atheroma, thrombosis and ischemic heart disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. Edinburgh, UK: Churchill Livingstone; 1994:1199-1227.
13. Meilahn EN, Lewis HK, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 1992;2:445-455.
14. Fuller JH, Keen H, Jarret RJ. Hemostatic variables associated with diabetes and its complications. BMJ. 1979;2:964-966.
15. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Della Volpe A, Polli E, and the PLAT Study Group. The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis. 1991;90:109-118.
16. Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorli P, Wu KK. Antithrombin III: associations with age, race, sex and cardiovascular risk factors. Thromb Haemost. 1994;72:551-556.
17. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet. 1991;338:850-851.
18. Cortellaro M. Antithrombin III and arterial disease. Lancet. 1991;338:1525-1526.
19. Hofman A, Grobbee DE, DeJong PTVM, Vanden Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Study. Eur J Epidemiol. 1991;7:403-422.
20. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. Geneva, Switzerland: World Health Organization; 1982.
21. Bots ML, van Swieten JC, Breteler MM, de Jong PTVM, van Gijn J, Hofman A, Grobbee DE. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet. 1993;341:1232-1237.
22. van der Bom JG, Bots ML, de Bruijn AM, Hofman A, Grobbee DE. Measurement of β-thromboglobulin in the elderly: findings from the Rotterdam Study. Fibrinolysis. 1994;8(suppl 2):157-159.
23. Rossi E, Mondonico P, Lombardi A, Preda L. Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulameters. Thromb Res. 1988;52:453-468.
24. Vangent CM, Vandervoort HA, De Bruijn AM. Cholesterol determinations: a comparative study of methods with special reference to enzymatic procedures. Clin Chem Acta. 1977;75:243-251.
25. Bernstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-595.
26. Grove TH. Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotung-state-magnesium. Clin Chim Acta. 1979;25:560-564.
27. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88:837-845.
28. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
29. Banerjee AK, Pearsons J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost. 1992;68:261-263.
30. Fowkes FGR. The measurement of atherosclerotic peripheral arterial disease in epidemiologic surveys. Int J Epidemiol. 1988;17:248-254.
31. Innerfield I, Goldrischer JD, Reicher Reiss H, Greenberg J. Serum antithrombin in coronary artery disease. Am J Clin Pathol. 1976;64:64-68.
32. Folsom A, Wu KK, Shahar E, Davies CE for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 1993;13:1829-1836.
33. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, della Volpe A, Polli E, and the PLAT Study Group. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results. Arterioscler Thromb. 1992;12:1063-1070.
34. Buller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med. 1989;87(suppl 3B):44S-48S.
35. Meade TW, North WRS, Chakrabarti R, Haines AP, Stirling Y. Population based distribution of haemostatic variables. Br Med Bull. 1977;33:283-288.
36. Tait RC, Walker ID, Islam SIAM, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol. 1993;84:476-480.